BNTC

Over the past six months, Benitec Biopharma's stock has experienced a decline, falling by 8.55% in the last week, 27.09% in the last month, and 34.14% over the past year as of October 8, 2026. The share price declined by 28.80% from October 1, 2025, to September 30, 2026, with a 52-week trading range between $8.52 and $16.76. Key events include the release of Full Year 2026 Financial Results on September 14, 2026, reporting a net loss of $45.5 million, an increase from 2025, though the company strengthened its cash position through equity financings. Third Quarter 2026 Financial Results were released on May 14, 2026. Clinical trial updates include an Oral Presentation of Interim Phase 1b/2a Clinical Study Results for high-dose BB-301 and continued durable improvements for low-dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting on April 28, 2026, and positive interim Phase 1b/2a results for BB-301 in OPMD reported around March 9, 2026. A Regulatory Update following a Type C Meeting with the FDA for the BB-301 Pivotal Study was announced on October 5, 2026. As of October 11, 2026, analysts have given BNTC an average rating of 'Moderate Buy' with an average 12-month price target of $24.00, with some firms like Citigroup, Wedbush, and HC Wainwright issuing positive ratings, while Wall Street Zen and Weiss Ratings downgraded the company to a 'sell' rating.